Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fig. 1

Participants flow diagram. *Fifteen MM patients were excluded from analysis at TP0 due to refusal of the study (n = 12) or no systemic ongoing therapy (n = 3; one patient on radiotherapy and two on follow-up post-VMP). **One MM patient did not receive the second dose due to concomitant bacterial infection. ***Three MM patients did not perform titration at TP2. §Three CML patients were excluded from analysis at TP0 due to refusal of the study (n = 2) or anti-SARS-CoV-2 IgG positivity at basal (n = 1). §§One CML patient did not receive the second dose because lost to follow-up. ^Fourteen MPN patients were excluded from analysis at TP0 due to refusal of the study (n = 12), no systemic ongoing therapy (n = 1) or anti-SARS-CoV-2 IgG positivity at basal (n = 1). ^^Two MPN patients did not perform titration at TP2

Back to article page